GV
₹48.01
-1.99(-3.98%)
GVBL₹48.01-3.98%
46/100
0100 · strongest
moderatepartial
Weights come from configuration, not from this page — each pillar links to the section below that explains it.
Income stmtHistory
Profitability
headline ratiosGrowth
compounded, from filed annual resultsSegment Results
₹ CrWorking Capital & Efficiency
days · ROCE %GVBL financial summary
For Mar 2026, Genomic Valley Biotech Ltd reported revenue of ₹0 crore, which fell 67.9% from the previous year. Net profit was ₹0 crore, which fell 91.7% year on year, on an operating margin of 15%. Earnings per share came in at ₹0.1. Over the 5 years from Mar 2021 to Mar 2026, revenue changed at a compound annual rate of 5.2%. The highest operating margin in that period was 52% in Mar 2025. Annual results are available for 12 financial years, from Mar 2015 to Mar 2026.
| Revenue | ₹0 crore |
|---|---|
| Net profit | ₹0 crore |
| Operating margin | 15% |
| EPS | ₹0.1 |